Krystal Biotech, Inc. (KRYS)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Krystal Biotech, Inc. reported revenue of $389.13M, up 33.9% from the prior year. The company was profitable, with a net margin of 52.6%. It held $1.33B in total assets against $114.23M in total liabilities.
Key ratios (FY2025)
41.5%
Operating margin
52.6%
Net margin
16.8%
Return on equity
+33.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $389.13M | $290.51M | $50.70M | $0 | $0 | — | — | — | — | — |
| Operating Income | $161.29M | $65.75M | -$109.62M | -$145.20M | -$68.28M | -$33.00M | -$22.08M | -$11.92M | -$4.77M | -$1.14M |
| Net Income | $204.83M | $89.16M | $10.93M | -$139.97M | -$69.57M | -$32.17M | -$19.09M | -$10.89M | -$7.92M | -$1.15M |
| EPS (Diluted) | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 | $-1.71 | — | — | — | — |
| Total Assets | $1.33B | $1.06B | $818.36M | $558.45M | $626.29M | $310.84M | $209.02M | $116.12M | $50.11M | $2.18M |
| Total Liabilities | $114.23M | $109.46M | $39.71M | $36.22M | $32.72M | $18.76M | $6.11M | $2.89M | $640.0K | $1.89M |
| Shareholders' Equity | $1.22B | $946.38M | $778.64M | $522.23M | $593.58M | $292.08M | $202.91M | $113.23M | $49.47M | $289.0K |
| Cash & Equivalents | $496.30M | $344.87M | $358.33M | $161.90M | $341.25M | $268.27M | $187.51M | $103.67M | $49.59M | $1.92M |
| Operating Cash Flow | $200.87M | $123.42M | -$88.80M | -$100.57M | -$47.94M | -$26.08M | -$18.69M | -$9.45M | — | — |
| Capital Expenditures | $11.95M | $4.24M | $11.80M | $52.98M | $68.34M | $14.84M | $6.40M | $2.23M | $210.0K | $15.0K |
| Shares Outstanding | 29.19M | 28.79M | 28.24M | 25.76M | 25.21M | 19.71M | 17.35M | 14.43M | 10.31M | 0 |